For example, studies have reported the antitumor activity of SFI003, a targeted inhibitor against SRSF3, in colorectal cancer, where SFI003 induced apoptosis in CRC cells through the SRSF3/DHCR24/ROS axis, and exhibited potent antitumor efficacy both in vitro and in vivo (Zhang et al., 2022). Here, SRSF3 is linked to colorectal carcinoma.